Healthcare
SAB Biotherapeutics, Inc.(SABS)
Live Price
Offline$3.33
-1.48% today
1Y Change
+84.92%
Window
Jun 20, 2025 โ Jun 10, 2026
- Market Cap
- $40.00M
- Revenue Growth
- -100.0%
- EPS Growth
- +106.0%
- Dividend Yield
- 0.0%
Coverage: 244 bars ยท Jun 20, 2025 โ Jun 10, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
SAB Biotherapeutics, Inc. (SABS) is a Healthcare stock with a market cap of $40.00M and listed on NASDAQ. The stock last traded around $3.33 and up 84.9% across the available one-year price window (Jun 20, 2025 โ Jun 10, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +106.0%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +106.0%, free cash flow -32.0% with operating margin 0.0% and ROIC -30.0%. Valuation is more restrained than many high-expectation growth names at P/E 5.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SABS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-100.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
P/E
Below sector median
5.4 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 8, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -100.0% and EPS is at +106.0%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.8% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 8, 2026 | โ | -9.5% | -10.0% | -17.3% |
2026 Mar 9, 2026 | -187.5% | +6.8% | +2.6% | -2.1% |
2025 Nov 14, 2025 | +64.4% | +8.0% | +21.9% | +23.5% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SABS
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SABS Max Drawdown
-33.80%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SABS and SPY.
Company Overview
SAB Biotherapeutics, Inc.
NASDAQ Global Market
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
- Leadership
- Samuel J. Reich
- IPO Date
- Feb 9, 2021
- Employees
- 63
- Street Address
- 2100 East 54th Street North
- Mailing
- Sioux Falls, SD, 57104
- Region
- Sioux Falls, SD, US
- Reporting Currency
- USD
- Investor Line
- 605 679 6980
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 5.4
- EV/EBITDA
- 1.8
- Price/Sales
- โ
- Price/Book
- 0.5
Growth
- Revenue
- -100.0%
- EPS
- +106.0%
- Free Cash Flow
- -32.0%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 15.2%
- ROIC
- -30.0%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 9.46
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.